34 results on '"Rosenberg, Yves D"'
Search Results
2. Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial
- Author
-
Sidhu, Mandeep S., Alexander, Karen P., Huang, Zhen, O'Brien, Sean M., Chaitman, Bernard R., Stone, Gregg W., Newman, Jonathan D., Boden, William E., Maggioni, Aldo P., Steg, Philippe Gabriel, Ferguson, Thomas B., Demkow, Marcin, Peteiro, Jesus, Wander, Gurpreet S., Phaneuf, Denis C., De Belder, Mark A., Doerr, Rolf, Alexanderson-Rosas, Erick, Polanczyk, Carisi A., Henriksen, Peter A., Conway, Dwayne S.G., Miro, Vicente, Sharir, Tali, Lopes, Renato D., Min, James K., Berman, Daniel S., Rockhold, Frank W., Balter, Stephen, Borrego, David, Rosenberg, Yves D., Bangalore, Sripal, Reynolds, Harmony R., Hochman, Judith S., and Maron, David J.
- Published
- 2022
- Full Text
- View/download PDF
3. Sex Differences in Revascularization, Treatment Goals, and Outcomes of Patients With Chronic Coronary Disease: Insights From the ISCHEMIA Trial
- Author
-
Reynolds, Harmony R., primary, Cyr, Derek D., additional, Merz, C. Noel Bairey, additional, Shaw, Leslee J., additional, Chaitman, Bernard R., additional, Boden, William E., additional, Alexander, Karen P., additional, Rosenberg, Yves D., additional, Bangalore, Sripal, additional, Stone, Gregg W., additional, Held, Claes, additional, Spertus, John, additional, Goetschalckx, Kaatje, additional, Bockeria, Olga, additional, Newman, Jonathan D., additional, Berger, Jeffrey S., additional, Elghamaz, Ahmed, additional, Lopes, Renato D., additional, Min, James K., additional, Berman, Daniel S., additional, Picard, Michael H., additional, Kwong, Raymond Y., additional, Harrington, Robert A., additional, Thomas, Boban, additional, O'Brien, Sean M., additional, Maron, David J., additional, Hochman, Judith S., additional, Mavromatis, Kreton, additional, Linefsky, Jason, additional, Miller, Todd, additional, Banerjee, Subhash, additional, Reynolds, Harmony R., additional, Donnino, Robert M., additional, Phillips, Lawrence M., additional, Saric, Muhamed, additional, Abdul‐Nour, Khaled, additional, Stone, Peter H., additional, Jang, James J., additional, Yee, Gennie, additional, Weitz, Steven, additional, Arnold, Suzanne, additional, O’Keefe, James Henry, additional, Shapiro, Michael D., additional, El‐Hajjar, Mohammad, additional, Sidhu, Mandeep S., additional, Fein, Steven A., additional, Torosoff, Mikhail T., additional, Lyubarova, Radmila, additional, Mookherjee, Sulagna, additional, Drzymalski, Krzysztof, additional, McFalls, Edward O., additional, Garcia, Santiago A., additional, Bertog, Stefan C., additional, Siddiqui, Rizwan A., additional, Ishani, Areef, additional, Hansen, Ronnell A., additional, Khouri, Michel Georges, additional, Goldberg, Jonathan L., additional, Goldweit, Richard, additional, Cohen, Ronny A., additional, Mirrer, Brooks, additional, Navarro, Victor, additional, Winchester, David E., additional, Kronenberg, Marvin, additional, Rogal, Philip, additional, McFarren, Christopher, additional, Heitner, John F., additional, Dauber, Ira M., additional, Cannan, Charles, additional, Sudarshan, Sriram, additional, Mehta, Puja K., additional, McDaniel, Michael, additional, Lerakis, Stamatios, additional, Quyyumi, Arshed, additional, Wenger, Nanette K., additional, Hedgepeth, Chester M., additional, Hurlburt, Heather, additional, Rosen, Alan, additional, Sahul, Zakir, additional, Booth, David, additional, Leung, Steve, additional, Abdel‐Latif, Ahmed, additional, Reda, Hassan, additional, Ziada, Khaled, additional, Setty, Sampoornima, additional, Barua, Rajat S., additional, Hage, Fadi, additional, Caldeira, Christiano, additional, Davies, James E., additional, Leesar, Massoud, additional, Heo, Jaekyeong, additional, Iskandrian, Amy, additional, Al Solaiman, Firas, additional, Singh, Satinder, additional, Dajani, Khaled, additional, Der Mesropian, Paul, additional, Sacco, Joseph, additional, McCandless, Brian, additional, Orgera, Marisa, additional, Arif, Imran, additional, Kerr, Hanan, additional, Trejo (Gutierrez), Jorge F., additional, Fletcher, Gerald, additional, Lane, Gary E., additional, Neeson, Lynn M., additional, Parikh, Pragnesh P., additional, Pollak, Peter M., additional, Shapiro, Brian P., additional, Landolfo, Kevin, additional, Gemignani, Anthony, additional, O’Rourke, Daniel, additional, Meadows, Judith L., additional, Call, Jason T., additional, Hannan, Joseph, additional, Bojar, Robert, additional, Kumar, Deepti, additional, Mukai, John, additional, Martin, Edward T., additional, Vorobiof, Gabriel, additional, Moorman, Alec, additional, Kinlay, Scott, additional, Hamburger, Robert J., additional, Rocco, Thomas P., additional, Bhatt, Deepak L., additional, Croce, Kevin, additional, Quin, Jacquelyn A., additional, Anumpa, Jati, additional, Zenati, Marco, additional, Faxon, David P., additional, Rayos, Glenn, additional, Seedhom, Ashraf, additional, Sullenberger, Lance, additional, Kumkumian, Gregory, additional, Sedlis, Steven P., additional, Donnino, Robert M., additional, Lorin, Jeffrey, additional, Tamis‐Holland, Jacqueline E., additional, Kornberg, Robert, additional, Leber, Robert, additional, Saba, Souheil, additional, Lee, Michael W., additional, Small, Delano R., additional, Nona, Wassim, additional, Alexander, Patrick B., additional, Rehman, Iram, additional, Badami, Umesh, additional, Marzo, Kevin, additional, Robbins, Inga H., additional, Levite, Howard A., additional, Shetty, Sanjay, additional, Patel, Mayuri, additional, Hamroff, Glenn S., additional, Little, Raymond W., additional, Zimbelman, Brandi D., additional, Lui, Charles Y., additional, Smith, Brigham R., additional, Vezina, Daniel P., additional, Khor, Lillian L., additional, Abraham, Josephine D., additional, Bull, David A., additional, McKellar, Stephen H., additional, Kotter, John, additional, Hu, Bob, additional, Labovitz, Arthur J., additional, Berlowitz, Michael, additional, Matar, Fadi, additional, Rodriguez, Fatima, additional, Schnittger, Ingela, additional, Fearon, William F., additional, Deedwania, Prakash, additional, Reddy, Kiran, additional, Sweeny, Joseph, additional, Spizzieri, Christopher, additional, Hochberg, Claudia P., additional, Salerno, William D., additional, Wyman, Ray, additional, Zarka, Amer, additional, Shah, Anil V., additional, Haldis, Thomas, additional, Kohn, Jeffrey A., additional, Girotra, Saket, additional, Almousalli, Omar, additional, Krishnam, Mayil S., additional, Milliken, Jeffrey C., additional, Patel, Pranav M., additional, Seto, Arnold H., additional, Harley, Kevin T., additional, Gibson, Michael A., additional, Allen, Byron J., additional, Coram, Rita, additional, Thomas, Sabu, additional, Schwartz, Ronald G., additional, Chen, Wei, additional, El Shahawy, Mahfouz, additional, Stafford, James, additional, Abernethy, William B., additional, Zurick, Andrew, additional, Meyer, Thomas M., additional, Morford, Ronald G., additional, Rutkin, Bruce, additional, Bokhari, Sabahat, additional, Sokol, Seth I., additional, Meisner, Jay, additional, Hamzeh, Ihab, additional, Misra, Arunima, additional, Wall, Matthew, additional, De Rosen, Veronica Lenges, additional, Alam, Mahboob, additional, Turner, Michael C., additional, Mulhearn, Thomas J., additional, Good, Arnold P., additional, Shammas, Nicolas W., additional, Chilton, Robert, additional, Nguyen, Patricia K., additional, Jezior, Matthew, additional, Gordon, Paul C., additional, Crain, Thomas, additional, Stenberg, Robert, additional, Pedalino, Ronald P., additional, Wiesel, Joseph, additional, Juang, George J., additional, Al‐Amoodi, Mohammed, additional, Wohns, David, additional, Lader, Ellis W., additional, Mumma, Michael, additional, Dharmarajan, Lekshmi, additional, McGarvey, Joseph F. X., additional, Downes, Thomas R., additional, Luckasen, Gary J., additional, Cheong, Benjamin, additional, Potluri, Srinivasa, additional, Mastouri, Ronald A., additional, Breall, Jeffery A., additional, Revtyak, George E., additional, Bazeley, Jonathan W., additional, Li, Dayuan, additional, Giedd, Kenneth, additional, Old, Wayne, additional, Burt, Francis, additional, Sokhon, Kozhaya, additional, Gopal, Deepika, additional, Valeti, Uma S., additional, Kobashigawa, Jon, additional, Govindan, Sajeev Chakanalil, additional, Nair, Rajesh Gopalan, additional, Manjunath, Cholenahally Nanjappa, additional, Moorthy, Nagaraja, additional, Manjunath, Satvic Cholenahally, additional, Narayanappa, Suryaprakash, additional, Pandit, Neeraj, additional, Nath, Ranjit Kumar, additional, Dwivedi, S. K., additional, Narain, V. S., additional, Chandra, Sharad, additional, Wander, Gurpreet S., additional, Tandon, Rohit, additional, Ralhan, Sarju, additional, Aslam, Naved, additional, Goyal, Abhishek, additional, Bhargava, Balram, additional, Karthikeyan, G., additional, Ramakrishnan, S., additional, Seth, Sandeep, additional, Yadav, Rakesh, additional, Singh, Sandeep, additional, Roy, Ambuj, additional, Parakh, Neeraj, additional, Verma, Sunil Kumar, additional, Narang, Rajiv, additional, Mishra, Sundeep, additional, Naik, Nitish, additional, Sharma, Gautam, additional, Choudhary, Shiv Kumar, additional, Patel, Chetan, additional, Gulati, Gurpreet, additional, Sharma, Sanjeev, additional, Bahl, V. K., additional, Mathew, Anoop, additional, Punnoose, Eapen, additional, Gadkari, Milind Avdhoot, additional, Gadage, Siddharth, additional, Pillay, Tapan Umesh, additional, Satheesh, Santhosh, additional, Mathur, Atul, additional, Kaul, Upendra, additional, Christopher, Johann, additional, Menon, Rajeev, additional, Kumar, Nirmal, additional, Oomman, Abraham, additional, Mao, Robert, additional, Solomon, Hilda, additional, Naik, Sudhir, additional, Khan, Sajeeda Parveen, additional, Grant, Purvez, additional, Kachru, Ranjan, additional, Ajit Kumar, V. K., additional, Ganapathi, Sanjay, additional, Jayakumar, K., additional, Sivadasanpillai, Harikrishnan, additional, Sasidharan, Bijulal, additional, Kapilamoorthy, T. R., additional, Polamuri, Praneeth, additional, Senior, Roxy, additional, Gurunathan, Sothinathan, additional, Karogiannis, Nikolaos, additional, Shah, Benoy N., additional, Trimlett, Richard HJ, additional, Rubens, Michael B., additional, Nicol, Edward D., additional, Mittal, Tarun K., additional, Hampson, Reinette, additional, Gamma, Reto Andreas, additional, de Belder, Mark A., additional, Thambyrajah, Jeet, additional, Nageh, Thuraia, additional, Davies, John R., additional, Lindsay, Steven J., additional, Kurian, John, additional, Jamil, Haqeel, additional, Raheem, Osama, additional, Hoye, Angela, additional, Donnelly, Patrick, additional, Valecka, Bernardas, additional, Chauhan, Anoop, additional, Barr, Craig, additional, Alfakih, Khaled, additional, Byrne, Jonathan, additional, Webb, Ian, additional, Henriksen, Peter, additional, OKane, Peter, additional, de Silva, Ramesh, additional, Conway, Dwayne S. G., additional, Sirker, Alexander A, additional, Hoole, Stephen P., additional, Witherow, Fraser N., additional, Johnston, Nicola, additional, Harbinson, Mark, additional, Walsh, Simon, additional, Douglas, Hanna, additional, Luckie, Matthew, additional, Sobolewska, Jolanta, additional, Jeetley, Paramjit, additional, Patel, Niket, additional, Kotecha, Tushar, additional, Travill, Christopher, additional, Karimullah, Iqbal, additional, Al‐Bustami, Mahmud, additional, Braganza, Denise, additional, Henderson, Robert, additional, Pointon, Kate, additional, Naik, Surendra, additional, Mathew, Thomas, additional, Berry, Colin, additional, Collison, Damien, additional, Roditi, Giles, additional, Moriarty, Andrew J., additional, Glover, Jason D., additional, Pradhan, Jiwan, additional, Mikhail, Ghada, additional, Francis, Darrel P., additional, Gosselin, Gilbert, additional, Diaz, Ariel, additional, Rheault, Philippe, additional, Barrero, Miguel, additional, Gagné, Carl‐Éric, additional, Pépin‐Dubois, Yanek, additional, Costa, Ricardo, additional, Sia, Ying Tung, additional, Lemay, Catherine, additional, Gisbert, Alejandro, additional, Gervais, Pierre, additional, Rheault, Alain, additional, Phaneuf, Denis Carl, additional, Garg, Pallav, additional, Chow, Benjamin J. W., additional, Hessian, Renee C., additional, Beanlands, Rob S., additional, Davies, Richard F., additional, Bainey, Kevin R., additional, Cheema, Asim N., additional, Bagai, Akshay, additional, Wald, Ron, additional, Goodman, Shaun, additional, Graham, John Joseph, additional, Peterson, Mark, additional, Chow, Chi‐Ming, additional, Abramson, Beth, additional, Cheema, Asim Nazir, additional, Vakani, Mohammad Tariq, additional, Cha, James, additional, Howarth, Andrew G, additional, Wong, Graham, additional, Uxa, Amar, additional, Galiwango, Paul, additional, Kassam, Saleem, additional, Mukherjee, Ashok, additional, Ricci, A. Joseph, additional, Lam, Andy, additional, Mehta, Shamir, additional, Udell, Jacob, additional, Généreux, Philippe, additional, Hameed, Adnan, additional, Daba, Ledjalem, additional, Hueb, Whady, additional, Rezende, Paulo Cury, additional, Silva, Expedito Eustáquio Ribeiro, additional, Hueb, Alexandre Ciappina, additional, Smanio, Paola Emanuela Poggio, additional, de Quadros, Alexandre Schaan, additional, Kalil, Renato Abdala Karam, additional, da Costa Vieira, José Luiz, additional, Grossmann, Gabriel, additional, de Oliveira, Pedro Píccaro, additional, Bridi, Leonardo, additional, Savaris, Simone, additional, Vitola, João V., additional, Cerci, Rodrigo J., additional, Farias, Fabio R., additional, Fernandes, Miguel M., additional, Marin‐Neto, José Antonio, additional, Schmidt, André, additional, de Oliveira Lima Filho, Moysés, additional, Oliveira, Ricardo Mendes, additional, Chierice, João Reynaldo Abbud, additional, Polanczyk, Carísi A., additional, Furtado, Mariana V., additional, Smidt, Luis F., additional, Carvalho, Antonio Carlos, additional, Pucci, Gustavo, additional, Lyra, Flavio, additional, Junior, Alvaro Rabelo Alves, additional, Dracoulakis, Marianna D. A., additional, Lima, Rodolfo G. S. D, additional, Figueiredo, Estevao, additional, Caramori, Paulo Ricardo, additional, Tumelero, Rogerio, additional, Dall’Orto, Frederico, additional, Mesquita, Claudio T., additional, Colafranseschi, Alexandre S., additional, Oliveira, Amarino C., additional, Carvalho, Luiz A., additional, Palazzo, Isabella C., additional, Sousa, Andre S., additional, da Silva, Expedito Eustáquio Ribeiro, additional, de Barros, Pedro Gabriel Melo, additional, de Pádua Silva Baptista, Luciana, additional, Rodrigues, Marcelo Jamus, additional, de Resende, Marcos Valério Coimbra, additional, Saraiva, Jose Francisco, additional, Costantini, Costantino, additional, Demkow, Marcin, additional, Pracon, Radoslaw, additional, Kepka, Cezary, additional, Teresinska, Anna, additional, Kryczka, Karolina, additional, Henzel, Jan, additional, Solecki, Mateusz, additional, Kaczmarska, Edyta, additional, Mazurek, Tomasz, additional, Drozdz, Jaroslaw, additional, Czarniak, Bartosz, additional, Frach, Malgorzata, additional, Szymczyk, Konrad, additional, Niedzwiecka, Iwona, additional, Sobczak, Sebastian, additional, Ciurus, Tomasz, additional, Jakubowski, Piotr, additional, Misztal‐Teodorczyk, Magdalena, additional, Teodorczyk, Dawid, additional, Fratczak, Aleksandra, additional, Szkopiak, Marcin, additional, Lebioda, Patrycja, additional, Wlodarczyk, Michal, additional, Plachcinska, Anna, additional, Kusmierek, Jacek, additional, Miller, Magdalena, additional, Marciniak, Halina, additional, Wojtczak‐Soska, Karolina, additional, Luczak, Katarzyna, additional, Tarchalski, Tomasz, additional, Cichocka‐Radwan, Anna, additional, Szwed, Hanna, additional, Szulczyk, Grazyna Anna, additional, Witkowski, Adam, additional, Kukula, Krzysztof, additional, Celinska‐Spodar, Malgorzta, additional, Zalewska, Joanna, additional, Gajos, Grzegorz, additional, Bury, Krzysztof, additional, Pruszczyk, Piotr, additional, Roik, Marek, additional, Loboz‐Grudzien, Krystyna, additional, Sokalski, Leszek, additional, Brzezinska, Barbara, additional, Lesiak, Maciej, additional, Lanocha, Magdalena, additional, Reczuch, Krzysztof W., additional, Kalarus, Zbigniew, additional, Swiatkowski, Andrzej, additional, Szulik, Mariola, additional, Musial, Wlodzimierz J., additional, Bockeria, Leo, additional, Petrosyan, Karen, additional, Trifonova, Tatiana, additional, Chernyavskiy, Alexander M., additional, Kretov, Evgeniy I., additional, Grazhdankin, Igor O., additional, Bershtein, Leonid L., additional, Sayganov, Sergey A., additional, Kuzmina‐Krutetskaya, Anastasia M., additional, Zbyshevskaya, Elizaveta V., additional, Katamadze, Nana O., additional, Demchenko, Elena A., additional, Kozlov, Pavel S., additional, Kozulin, Vikentiy Y., additional, Lubinskaya, Ekaterina I., additional, Lopez‐Sendon, Jose, additional, Castro, Almudena, additional, Salicio, Elena Refoyo, additional, Guzman, Gabriela, additional, Galeote, Gabriel, additional, Valbuena, Silvia, additional, Peteiro, Jesús, additional, Martínez‐Ruíz, María Dolores, additional, Pérez‐Fernández, Ruth, additional, Cuenca‐Castillo, José J., additional, Flores‐Ríos, Xacobe, additional, Prada‐Delgado, Óscar, additional, Barge‐Caballero, Gonzalo, additional, Juanatey, Jose Ramon Gonzalez, additional, Bayarri, Miguel Souto, additional, Nuñez, Virginia Pubull, additional, Sanchez, Raymundo Ocaranza, additional, Alvarez, Belen Cid, additional, Gil, Carlos Peña, additional, Monzonis, Amparo Martinez, additional, Sionis, Alessandro, additional, Perales, Montserrat Vila, additional, Padró, Josep Maria, additional, Peñaranda, Antonio Serra, additional, Picart, Joan García, additional, Iglesias, Antonino Ginel, additional, Marimon, Xavier Garcia‐Moll, additional, Lladó, Guillem Pons, additional, Costa, Francesc Carreras, additional, Miro, Vicente, additional, Diez, Jose L., additional, Calvillo, Pilar, additional, Ortuño, F. Marin, additional, Chávarri, M. Valdés, additional, Montolliu, A. Tello, additional, Bermudez, E. Pinar, additional, De La Morena, G., additional, Blancas, Montserrat Gracida, additional, Luena, Jose Enrique Castillo, additional, Fernandez‐Aviles, Francisco, additional, Chen, Jiyan, additional, Wu, Yongjian, additional, Ma, Yitong, additional, Yang, Yining, additional, Ji, Zheng, additional, Yang, Xinchun, additional, Lin, Wenhua, additional, Zeng, Hesong, additional, Fu, Xin, additional, Yang, Bin, additional, Wang, Songtao, additional, Cheng, Gong, additional, Zhao, Yulan, additional, Fang, Xuehua, additional, Zeng, Qiutang, additional, Su, Xi, additional, Li, Qingxian, additional, Nie, Shao‐ping, additional, Yu, Qin, additional, Wang, Jian’an, additional, Zhang, Shuyang, additional, Liu, Zhenyu, additional, Perna, Gian Piero, additional, Marini, Marco, additional, Gabrielli, Gabriele, additional, Provasoli, Stefano, additional, Verna, Edoardo, additional, Monti, Lorenzo, additional, Nardi, Barbara, additional, Di Chiara, Antonio, additional, Mortara, Andrea, additional, Galvani, Marcello, additional, Ottani, Filippo, additional, Sicuro, Marco, additional, Calabro, Paolo, additional, Formisano, Tiziana, additional, Tarantini, Giuseppe, additional, Cucchini, Umberto, additional, Andres, Anto Luigi, additional, Racca, Emanuela, additional, Briguori, Carlo, additional, Amati, Roberto, additional, Vergoni, William, additional, Russo, Aldo, additional, Fanelli, Raffaele, additional, Poh, Kian‐Keong, additional, Chai, Ping, additional, Lau, Titus, additional, Loh, Joshua P., additional, Tay, Edgar L., additional, Teoh, Kristine, additional, Teo, Lynette L., additional, Ong, Ching‐Ching, additional, Wong, Raymond C., additional, Loh, Poay‐Huan, additional, Kofidis, Theodoros, additional, Chan, Wan Xian, additional, Chan, Koo Hui, additional, Foo, David, additional, Kong, Jason Loh Kwok, additional, Er, Ching Min, additional, Jafary, Fahim Haider, additional, Chua, Terrance, additional, Doerr, Rolf, additional, Stumpf, Juergen, additional, Matschke, Klaus, additional, Simonis, Gregor, additional, Kadalie, Clemens T., additional, Sechtem, Udo, additional, Ong, Peter, additional, Schulze, P. Christian, additional, Goebel, Bjoern, additional, Lenk, Karsten, additional, Nickenig, Georg, additional, Schuchlenz, Herwig, additional, Weikl, Stefan, additional, Lang, Irene Marthe, additional, Huber, Kurt, additional, Jakl‐Kotauschek, Gabriele, additional, Vertes, Andras, additional, Varga, Albert, additional, Fontos, Geza, additional, Merkely, Bela, additional, Kerecsen, Gabor, additional, Hinic, Sasa, additional, Zdravkovic, Marija, additional, Mudrenovic, Vladan, additional, Crnokrak, Bogdan, additional, Beleslin, Branko D., additional, Boskovic, Nikola N., additional, Petrovic, Marija T., additional, Dobric, Milan R., additional, Markovic, Zeljko Z., additional, Mladenovic, Ana S., additional, Cemerlic‐Adjic, Nada, additional, Davidovic, Goran, additional, Vucic, Rada, additional, Dekleva, Milica Nikola, additional, Stankovic, Goran, additional, Apostolovic, Svetlana, additional, Escobedo, Jorge, additional, Baleón‐Espinosa, Rubén, additional, Campos‐Santaolalla, Arturo S., additional, Durán‐Cortés, Elihú, additional, Flores‐Palacios, José M., additional, García‐Rincón, Andrés, additional, Jiménez‐Santos, Moisés, additional, Peñafiel, Joaquín V., additional, Ortega‐Ramírez, José A., additional, Valdespino‐Estrada, Aquiles, additional, Rosas, Erick Alexánderson, additional, Selvanayagam, Joseph B., additional, Joseph, Majo X., additional, Thambar, Suku T., additional, Beltrame, John F., additional, Hillis, Graham S., additional, Thuaire, Christophe, additional, Dutoiu, Téodora, additional, Steg, Philippe Gabriel, additional, Juliard, Jean‐Michel, additional, Slama, Michel S., additional, El Mahmoud, Rami, additional, Nicollet, Eric, additional, Goube, Pascal, additional, Barone‐Rochette, Gilles, additional, Furber, Alain, additional, Bière, Loïc, additional, Laucevicius, Aleksandras, additional, Celutkiene, Jelena, additional, Kedhi, Elvin, additional, Timmer, Jorik, additional, Hermanides, Rik, additional, Kaplan, Eliza, additional, Riezebos, Robert K., additional, Samadi, Pouneh, additional, van Dongen, Elise, additional, Niehe, Sander R., additional, Suryapranata, Harry, additional, van Vugt, Stijn, additional, Ramos, Ruben, additional, Cacela, Duarte, additional, Santana, Ana, additional, Fiarresga, Antonio, additional, Sousa, Lidia, additional, Marques, Hugo, additional, Patricio, Lino, additional, Bernanrdes, Luis, additional, Rio, Pedro, additional, Carvalho, Ramiro, additional, Ferreira, Rui, additional, Silva, Tiago, additional, Rodrigues, Ines, additional, Modas, Pedro, additional, Portugal, Guilherme, additional, Fragata, Jose, additional, Pinto, Fausto J., additional, Menezes, Miguel Nobre, additional, Lopes, Guilhermina Cantinho, additional, Almeida, Ana Gomes, additional, Silva, Pedro Canas, additional, Nobre, Angelo, additional, Francisco, Ana Rita, additional, Ferreira, Nuno, additional, Lopes, Ricardo L., additional, Guzman, Luis, additional, Figal, Julio César, additional, Méndiz, Oscar, additional, Cortés, Claudia, additional, Favaloro, Roberto René, additional, Alvarez, Carlos, additional, Courtis, Javier, additional, Zeballos, Gabriela, additional, Schiavi, Lilia, additional, Rubio, Mariano, additional, Devlin, Gerard Patrick, additional, Fisher, Raewyn, additional, Stewart, Ralph Alan Huston, additional, White, Harvey Douglas, additional, Benatar, Jocelyne, additional, Kedev, Sasko, additional, Mitevska, Irena Peovska, additional, Kostovska, Elizabeta Srbinovska, additional, Pejkov, Hristo, additional, Eggers, Kai, additional, Frostfelt, Gunnar, additional, Johnston, Nina, additional, Olsowka, Maciej, additional, Åkerblom, Axel, additional, Soveri, Inga, additional, Aspberg, Johannes, additional, Sharir, Tali, additional, Elian, Dan, additional, Kerner, Arthur, additional, Massalha, Samia, additional, Fukuda, Keiichi, additional, Kohsaka, Shun, additional, Yasuda, Satoshi, additional, Nishimura, Shigeyuki, additional, Van de Werf, Frans, additional, Claes, Kathleen, additional, Hung, Chung‐Lieh, additional, Yun, Chun‐Ho, additional, Hou, Charles Jia‐Yin, additional, Kuo, Jen‐Yuan, additional, Yeh, Hung‐I, additional, Hung, Ta‐Chuan, additional, Li, Jiun‐Yi, additional, Chien, Chen‐Yen, additional, Tsai, Cheng‐Ting, additional, Liu, Chun‐Chieh, additional, Yu, Fa‐Chang, additional, Lin, Yueh‐Hung, additional, Lan, Wei‐Ren, additional, Yen, Chih‐Hsuan, additional, Tsai, Jui‐Peng, additional, Sung, Kuo‐Tzu, additional, Ntsekhe, Mpiko, additional, Pandie, Shaheen, additional, Viljoen, Charle A., additional, De Andrade, Marianne, additional, Moccetti, Tiziano, additional, Rossi, M. Grazia, additional, Abdelhamid, Magdy, additional, Adel, Ahmed, additional, Kamal, Ahmed, additional, Mahrous, Hossam, additional, El Kaffas, Sameh, additional, El Fishawy, Hussien, additional, Pop, Calin, additional, Claudia, Matei, additional, Popescu, Bogdan A., additional, Ginghina, Carmen, additional, Deleanu, Dan, additional, Iliescu, Vlad A., additional, Al‐Mallah, Mouaz H., additional, Aljzeeri, Ahmed, additional, Najm, Hani, additional, Alghamdi, Ali, additional, Ramos, Walter Enrique Mogrovejo, additional, Kuanprasert, Srun, additional, Prommintikul, Arintaya, additional, Nawarawong, Weerachai, additional, Woragidpoonpol, Surin, additional, Tepsuwan, Thitipong, additional, Taksaudom, Noppon, additional, Rimsukcharoenchai, Chataroon, additional, Euathrongchit, Juntima, additional, Wannasopha, Yutthaphan, additional, Yamwong, Sukit, additional, Sritara, Piyamitr, additional, Aramcharoen, Suthara, additional, Meemuk, Krissada, additional, Khairuddin, Ahmad, additional, Hadi, Hafidz Abd, additional, and Yahaya, Shaiful Azmi, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Sex Differences in Revascularization, Treatment Goals, and Outcomes of Patients With Chronic Coronary Disease : Insights From the ISCHEMIA Trial
- Author
-
Reynolds, Harmony R., Cyr, Derek D., Bairey Merz, C. Noel, Shaw, Leslee J., Chaitman, Bernard R., Boden, William E., Alexander, Karen P., Rosenberg, Yves D., Bangalore, Sripal, Stone, Gregg W., Held, Claes, Spertus, John, Goetschalckx, Kaatje, Bockeria, Olga, Newman, Jonathan D., Berger, Jeffrey S., Elghamaz, Ahmed, Lopes, Renato D., Min, James K., Berman, Daniel S., Picard, Michael H., Kwong, Raymond Y., Harrington, Robert A., Thomas, Boban, O'Brien, Sean M., Maron, David J., Hochman, Judith S., Reynolds, Harmony R., Cyr, Derek D., Bairey Merz, C. Noel, Shaw, Leslee J., Chaitman, Bernard R., Boden, William E., Alexander, Karen P., Rosenberg, Yves D., Bangalore, Sripal, Stone, Gregg W., Held, Claes, Spertus, John, Goetschalckx, Kaatje, Bockeria, Olga, Newman, Jonathan D., Berger, Jeffrey S., Elghamaz, Ahmed, Lopes, Renato D., Min, James K., Berman, Daniel S., Picard, Michael H., Kwong, Raymond Y., Harrington, Robert A., Thomas, Boban, O'Brien, Sean M., Maron, David J., and Hochman, Judith S.
- Abstract
Background Women with chronic coronary disease are generally older than men and have more comorbidities but less atherosclerosis. We explored sex differences in revascularization, guideline‐directed medical therapy, and outcomes among patients with chronic coronary disease with ischemia on stress testing, with and without invasive management. Methods and Results The ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial randomized patients with moderate or severe ischemia to invasive management with angiography, revascularization, and guideline‐directed medical therapy, or initial conservative management with guideline‐directed medical therapy alone. We evaluated the primary outcome (cardiovascular death, myocardial infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest) and other end points, by sex, in 1168 (22.6%) women and 4011 (77.4%) men. Invasive group catheterization rates were similar, with less revascularization among women (73.4% of invasive‐assigned women revascularized versus 81.2% of invasive‐assigned men; P<0.001). Women had less coronary artery disease: multivessel in 60.0% of invasive‐assigned women and 74.8% of invasive‐assigned men, and no ≥50% stenosis in 12.3% versus 4.5% (P<0.001). In the conservative group, 4‐year catheterization rates were 26.3% of women versus 25.6% of men (P=0.72). Guideline‐directed medical therapy use was lower among women with fewer risk factor goals attained. There were no sex differences in the primary outcome (adjusted hazard ratio [HR] for women versus men, 0.93 [95% CI, 0.77–1.13]; P=0.47) or the major secondary outcome of cardiovascular death/myocardial infarction (adjusted HR, 0.93 [95% CI, 0.76–1.14]; P=0.49), with no significant sex‐by‐treatment‐group interactions. Conclusions Women had less extensive coronary artery disease and, therefore, lower revascularization rates in the invasive group. Despite lower risk
- Published
- 2024
- Full Text
- View/download PDF
5. Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study.
- Author
-
Mathew, Roy O., Sidhu, Mandeep S., Rihal, Charanjit S., Lennon, Ryan, El-Hajjar, Mohammed, Yager, Neil, Lyubarova, Radmila, Abdul-Nour, Khaled, Weitz, Steven, O'Cochlain, D. Fearghas, Murthy, Vishakantha, Levisay, Justin, Marzo, Kevin, Graham, John, Dzavik, Vlad, So, Derek, Goodman, Shaun, Rosenberg, Yves D., Pereira, Naveen, and Farkouh, Michael E.
- Abstract
Purpose: Chronic kidney disease (CKD) is a risk factor for ischemic and bleeding events with dual antiplatelet therapy after percutaneous coronary intervention (PCI). Whether the presence of CYP2C19 loss of function (LOF) alleles modifies this risk, and whether a genotype-guided (GG) escalation of P2Y
12 inhibitor therapy post PCI is safe in this population is unclear. Methods: This was a post hoc analysis of randomized patients in TAILOR PCI. Patients were divided into two groups based on estimated glomerular filtration rate (eGFR) threshold of < 60 ml/min/1.73 m2 for CKD (n = 539) and non-CKD (n = 4276). The aggregate of cardiovascular death, stroke, myocardial infarction, stent thrombosis, and severe recurrent coronary ischemia at 12-months post-PCI was assessed as the primary endpoint. Secondary endpoint was major or minor bleeding. Results: Mean (standard deviation) eGFR among patients with CKD was 49.5 (8.4) ml/min/1.72 m2 . Among all patients, there was no significant interaction between randomized strategy and CKD status for any endpoint. Among LOF carriers, the interaction between randomized strategy and CKD status on composite ischemic outcome was not significant (p = 0.2). GG strategy was not associated with an increased risk of bleeding in either CKD group. Conclusions: In this exploratory analysis, escalation of P2Y12 inhibitor therapy following a GG strategy did not reduce the primary outcome in CKD. However, P2Y12 inhibitor escalation following a GG strategy was not associated with increased bleeding risk in CKD. Larger studies in CKD are needed. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT01742117?term=TAILOR-PCI&draw=2&rank=1. NCT01742117. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
6. Outcomes of Participants with Diabetes in the ISCHEMIA Trials
- Author
-
Newman, Jonathan D., Anthopolos, Rebecca, Mancini, G.B. John, Bangalore, Sripal, Reynolds, Harmony R., Kunichoff, Dennis F., Senior, Roxy, Peteiro, Jesus, Bhargava, Balram, Garg, Pallav, Escobedo, Jorge, Doerr, Rolf, Mazurek, Tomasz, Gonzalez-Juanatey, Jose, Gajos, Grzegorz, Briguori, Carlo, Cheng, Hong, Vertes, Andras, Mahajan, Sandeep, Guzman, Luis A., Keltai, Matyas, Maggioni, Aldo P., Stone, Gregg W., Berger, Jeffrey S., Rosenberg, Yves D., Boden, William E., Chaitman, Bernard R., Fleg, Jerome L., Hochman, Judith S., and Maron, David J.
- Published
- 2021
- Full Text
- View/download PDF
7. A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing
- Author
-
Kimmel, Stephen E, French, Benjamin, Kasner, Scott E, Johnson, Julie A, Anderson, Jeffrey L, Gage, Brian F, Rosenberg, Yves D, Eby, Charles S, Madigan, Rosemary A, McBane, Robert B, Abdel-Rahman, Sherif Z, Stevens, Scott M, Yale, Steven, Mohler, Emile R, Fang, Margaret C, Shah, Vinay, Horenstein, Richard B, Limdi, Nita A, Muldowney, James AS, Gujral, Jaspal, Delafontaine, Patrice, Desnick, Robert J, Ortel, Thomas L, Billett, Henny H, Pendleton, Robert C, Geller, Nancy L, Halperin, Jonathan L, Goldhaber, Samuel Z, Caldwell, Michael D, Califf, Robert M, and Ellenberg, Jonas H
- Subjects
Hematology ,Genetics ,Clinical Research ,Clinical Trials and Supportive Activities ,Evaluation of treatments and therapeutic interventions ,Development of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,5.1 Pharmaceuticals ,Adult ,Aged ,Algorithms ,Anticoagulants ,Aryl Hydrocarbon Hydroxylases ,Cytochrome P-450 CYP2C9 ,Double-Blind Method ,Female ,Follow-Up Studies ,Genotype ,Hemorrhage ,Humans ,International Normalized Ratio ,Male ,Pharmacogenetics ,Thromboembolism ,Treatment Failure ,Vitamin K Epoxide Reductases ,Warfarin ,COAG Investigators ,Medical and Health Sciences ,General & Internal Medicine - Abstract
BackgroundThe clinical utility of genotype-guided (pharmacogenetically based) dosing of warfarin has been tested only in small clinical trials or observational studies, with equivocal results.MethodsWe randomly assigned 1015 patients to receive doses of warfarin during the first 5 days of therapy that were determined according to a dosing algorithm that included both clinical variables and genotype data or to one that included clinical variables only. All patients and clinicians were unaware of the dose of warfarin during the first 4 weeks of therapy. The primary outcome was the percentage of time that the international normalized ratio (INR) was in the therapeutic range from day 4 or 5 through day 28 of therapy.ResultsAt 4 weeks, the mean percentage of time in the therapeutic range was 45.2% in the genotype-guided group and 45.4% in the clinically guided group (adjusted mean difference, [genotype-guided group minus clinically guided group], -0.2; 95% confidence interval, -3.4 to 3.1; P=0.91). There also was no significant between-group difference among patients with a predicted dose difference between the two algorithms of 1 mg per day or more. There was, however, a significant interaction between dosing strategy and race (P=0.003). Among black patients, the mean percentage of time in the therapeutic range was less in the genotype-guided group than in the clinically guided group. The rates of the combined outcome of any INR of 4 or more, major bleeding, or thromboembolism did not differ significantly according to dosing strategy.ConclusionsGenotype-guided dosing of warfarin did not improve anticoagulation control during the first 4 weeks of therapy. (Funded by the National Heart, Lung, and Blood Institute and others; COAG ClinicalTrials.gov number, NCT00839657.).
- Published
- 2013
8. Abstract 16998: Gender and Age Specific Baseline Predictors of MACE in PEACE Trial Identified by Machine Learning
- Author
-
Xin, Victoria, Hayashi, Scout, Husain, Anwar, Hasan, Ahmed A, Dey, Amit, Banerjee, Avantika, Atkinson, Ian, Dandi, Gauri, Qureshi, Khizar, Lewis, Natalie, Mahmood, Nayab, Hasan, Noah, Haq, Nowreen, Gani, Nuha, Mallick, Zyannah, and Rosenberg, Yves D
- Published
- 2020
- Full Text
- View/download PDF
9. Abstract 16309: Age Specific Baseline Predictors of All-cause Mortality in Systolic Blood Pressure Intervention Trial (SPRINT) Identified by Machine Learning
- Author
-
Gani, Nuha, Husain, Anwar, Dandi, Gauri, Atkinson, Ian, Mallick, Zyannah, Banerjee, Avantika, Xin, Victoria, Hayashi, Scout, Lewis, Natalie, Mahmood, Nayab, Hasan, Noah, Qureshi, Khizar, Dey, Amit, Rosenberg, Yves D, and Hasan, Ahmed A
- Published
- 2020
- Full Text
- View/download PDF
10. Abstract 15971: Gender, Race, and Age Specific Baseline Predictors of All-Cause Mortality in BARI2D Trial Identified by Machine Learning
- Author
-
Mallick, Zyannah, Mahmood, Nayab, Dandi, Gauri, Haq, Nowreen, Banerjee, Avantika, Atkinson, Ian, Gani, Nuha, Xin, Victoria, Hayashi, Scout, Lewis, Natalie, Qureshi, Khizar, Hasan, Noah, Dey, Amit, Husain, Anwar, Rosenberg, Yves D, and Hasan, Ahmed A
- Published
- 2020
- Full Text
- View/download PDF
11. Abstract 15924: Identification of Gender- and Age-specific Top Predictors of Hospitalization Due to Heart Failure Using Machine Learning in TOPCAT
- Author
-
Dandi, Gauri, Gani, Nuha, Mallick, Zyannah, Banerjee, Avantika, Atkinson, Ian, Xin, Victoria, Qureshi, Khizar, Lewis, Natalie, Mahmood, Nayab, Hasan, Noah, Hayashi, Scout, Haq, Nowreen, Dey, Amit, Husain, Anwar, Rosenberg, Yves D, and Hasan, Ahmed A
- Published
- 2020
- Full Text
- View/download PDF
12. Abstract 15572: Gender, Race, and Age Specific Baseline Predictors of All-cause Mortality in STICHES Trial Identified by Machine Learning
- Author
-
Atkinson, Ian C, Husain, Anwar, Dandi, Gauri, Gani, Nuha, Mallick, Zyannah, Xin, Victoria, Hayashi, Scout, Lewis, Natalie, Hasan, Noah, Mahmood, Nayab, Qureshi, Khizar, Banerjee, Avantika, Dey, Amit, Rosenberg, Yves D, and Hasan, Ahmed A
- Published
- 2020
- Full Text
- View/download PDF
13. Abstract 13030: Causes of Cardiovascular and Non-cardiovascular Mortality in the Ischemia Trial
- Author
-
Sidhu, Mandeep S, Alexander, Karen P, Huang, Zhen, O’Brien, Sean M, Chaitman, Bernard R, Stone, Gregg W, Newman, Jonathan D, Boden, William E, Maggioni, Aldo P, Steg, Philippe Gabriel, Ferguson, T Bruce, Demkow, Marcin, Peteiro, Jesus, Wander, Gurpreet S, de Belder, Mark A, Szwed, Hanna, Doerr, Rolf, Alexanderson, Erick, Polanczyk, Carisi, Henriksen, Peter, Conway, Dwayne, Miro, Vicente, Sharir, Tali, Rosenberg, Yves D, Bangalore, Sripal, Reynolds, Harmony R, Hochman, Judith S, and Maron, David J
- Published
- 2020
- Full Text
- View/download PDF
14. Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study
- Author
-
Mathew, Roy O., primary, Sidhu, Mandeep S., additional, Rihal, Charanjit S., additional, Lennon, Ryan, additional, El-Hajjar, Mohammed, additional, Yager, Neil, additional, Lyubarova, Radmila, additional, Abdul-Nour, Khaled, additional, Weitz, Steven, additional, O’Cochlain, D. Fearghas, additional, Murthy, Vishakantha, additional, Levisay, Justin, additional, Marzo, Kevin, additional, Graham, John, additional, Dzavik, Vlad, additional, So, Derek, additional, Goodman, Shaun, additional, Rosenberg, Yves D., additional, Pereira, Naveen, additional, and Farkouh, Michael E., additional
- Published
- 2022
- Full Text
- View/download PDF
15. Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review
- Author
-
Marquis-Gravel, Guillaume, Moliterno, David J., Francis, Darrel P., Jüni, Peter, Rosenberg, Yves D., Claessen, Bimmer E., Mentz, Robert J., Mehran, Roxana, Cutlip, Donald E., Chauhan, Cynthia, Quella, Susan, Zannad, Faiez, and Goodman, Shaun G.
- Subjects
Percutaneous Coronary Intervention ,Research Design ,Humans ,Coronary Artery Disease ,Quality Improvement ,Article ,Randomized Controlled Trials as Topic - Abstract
The role of percutaneous coronary interventions in addition to medical therapy for patients with stable coronary artery disease continues to be debated in routine clinical practice, despite more than 2 decades of randomized controlled trials. The residual uncertainty arises from particular challenges facing revascularization trials. Which endpoint do doctors care about, and which do patients care about? Which participants should be enrolled? What background medical therapy should we use? When is placebo control relevant? In this paper, we discuss how these questions can be approached and examine the merits and disadvantages of possible options. Engaging multiple stakeholders, including patients, researchers, regulators, and funders, to ensure the design elements are methodologically valid and clinically meaningful should be an aspirational goal in the development of future trials.
- Published
- 2020
16. Study design for the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care (IMMEDIATE) Trial: A double-blind randomized controlled trial of intravenous glucose, insulin, and potassium for acute coronary syndromes in emergency medical services
- Author
-
Selker, Harry P., Beshansky, Joni R., Griffith, John L., DʼAgostino, Ralph B., Massaro, Joseph M., Udelson, James E., Rashba, Eric J., Ruthazer, Robin, Sheehan, Patricia R., Desvigne-Nickens, Patrice, Rosenberg, Yves D., Atkins, James M., Sayah, Assaad J., Aufderheide, Tom P., Rackley, Charles E., Opie, Lionel H., Lambrew, Costas T., Cobb, Leonard A., MacLeod, Bruce A., Ingwall, Joanne S., Zalenski, Robert J., and Apstein, Carl S.
- Published
- 2012
- Full Text
- View/download PDF
17. Intensive Glucose Lowering and Cardiovascular Outcomes
- Author
-
Gerstein, Hertzel C., Miller, Michael E., and Rosenberg, Yves D.
- Published
- 2011
18. Improving the Design of Future PCI Trials for Stable Coronary Artery Disease
- Author
-
Marquis-Gravel, Guillaume, primary, Moliterno, David J., additional, Francis, Darrel P., additional, Jüni, Peter, additional, Rosenberg, Yves D., additional, Claessen, Bimmer E., additional, Mentz, Robert J., additional, Mehran, Roxana, additional, Cutlip, Donald E., additional, Chauhan, Cynthia, additional, Quella, Susan, additional, Zannad, Faiez, additional, and Goodman, Shaun G., additional
- Published
- 2020
- Full Text
- View/download PDF
19. Lack of Association Between Thiazolidinediones and Macular Edema in Type 2 Diabetes: The ACCORD Eye Substudy
- Author
-
Ambrosius, Walter T., Danis, Ronald P., Goff, David C., Jr, Greven, Craig M., Gerstein, Hertzel C., Cohen, Robert M., Riddle, Matthew C., Miller, Michael E., Buse, John B., Bonds, Denise E., Peterson, Kevin A., Rosenberg, Yves D., Perdue, Letitia H., Esser, Barbara A., Seaquist, Lea A., Felicetta, James V., and Chew, Emily Y.
- Published
- 2010
20. Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial
- Author
-
Kimmel, Stephen E., French, Benjamin, Anderson, Jeffrey L., Gage, Brian F., Johnson, Julie A., Rosenberg, Yves D., Geller, Nancy L., Kasner, Scott E., Eby, Charles S., Joo, Jungnam, Caldwell, Michael D., Goldhaber, Samuel Z., Hart, Robert G., Cifelli, Denise, Madigan, Rosemary, Brensinger, Colleen M., Goldberg, Suzanne, Califf, Robert M., and Ellenberg, Jonas H.
- Published
- 2013
- Full Text
- View/download PDF
21. Gender differences in advanced heart failure: insights from the BEST study
- Author
-
Ghali, Jalal K, Krause-Steinrauf, Heidi J, Adams, Kirkwood F, Jr, Khan, Steven S, Rosenberg, Yves D, Yancy, Clyde W, Jr, Young, James B, Goldman, Steven, Peberdy, Mary Ann, and Lindenfeld, JoAnn
- Published
- 2003
- Full Text
- View/download PDF
22. Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis
- Author
-
Bagai, Akshay, primary, Alexander, Karen P., additional, Berger, Jeffrey S., additional, Senior, Roxy, additional, Sajeev, Chakkanalil, additional, Pracon, Radoslaw, additional, Mavromatis, Kreton, additional, Lopez-Sendón, Jose Luis, additional, Gosselin, Gilbert, additional, Diaz, Ariel, additional, Perna, Gian, additional, Drozdz, Jarozlaw, additional, Humen, Dennis, additional, Petrauskiene, Birute, additional, Cheema, Asim N., additional, Phaneuf, Denis, additional, Banerjee, Subhash, additional, Miller, Todd D., additional, Kedev, Sasko, additional, Schuchlenz, Herwig, additional, Stone, Gregg W., additional, Goodman, Shaun G., additional, Mahaffey, Kenneth W., additional, Jaffe, Allan S., additional, Rosenberg, Yves D., additional, Bangalore, Sripal, additional, Newby, L. Kristin, additional, Maron, David J., additional, Hochman, Judith S., additional, and Chaitman, Bernard R., additional
- Published
- 2017
- Full Text
- View/download PDF
23. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.
- Author
-
Packer, Douglas L., Mark, Daniel B., Robb, Richard A., Monahan, Kristi H., Bahnson, Tristram D., Poole, Jeanne E., Noseworthy, Peter A., Rosenberg, Yves D., Jeffries, Neal, Mitchell, L. Brent, Flaker, Greg C., Pokushalov, Evgeny, Romanov, Alexander, Bunch, T. Jared, Noelker, Georg, Ardashev, Andrey, Revishvili, Amiran, Wilber, David J., Cappato, Riccardo, and Kuck, Karl-Heinz
- Abstract
Importance: Catheter ablation is effective in restoring sinus rhythm in atrial fibrillation (AF), but its effects on long-term mortality and stroke risk are uncertain.Objective: To determine whether catheter ablation is more effective than conventional medical therapy for improving outcomes in AF.Design, Setting, and Participants: The Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation trial is an investigator-initiated, open-label, multicenter, randomized trial involving 126 centers in 10 countries. A total of 2204 symptomatic patients with AF aged 65 years and older or younger than 65 years with 1 or more risk factors for stroke were enrolled from November 2009 to April 2016, with follow-up through December 31, 2017.Interventions: The catheter ablation group (n = 1108) underwent pulmonary vein isolation, with additional ablative procedures at the discretion of site investigators. The drug therapy group (n = 1096) received standard rhythm and/or rate control drugs guided by contemporaneous guidelines.Main Outcomes and Measures: The primary end point was a composite of death, disabling stroke, serious bleeding, or cardiac arrest. Among 13 prespecified secondary end points, 3 are included in this report: all-cause mortality; total mortality or cardiovascular hospitalization; and AF recurrence.Results: Of the 2204 patients randomized (median age, 68 years; 37.2% female; 42.9% had paroxysmal AF and 57.1% had persistent AF), 89.3% completed the trial. Of the patients assigned to catheter ablation, 1006 (90.8%) underwent the procedure. Of the patients assigned to drug therapy, 301 (27.5%) ultimately received catheter ablation. In the intention-to-treat analysis, over a median follow-up of 48.5 months, the primary end point occurred in 8.0% (n = 89) of patients in the ablation group vs 9.2% (n = 101) of patients in the drug therapy group (hazard ratio [HR], 0.86 [95% CI, 0.65-1.15]; P = .30). Among the secondary end points, outcomes in the ablation group vs the drug therapy group, respectively, were 5.2% vs 6.1% for all-cause mortality (HR, 0.85 [95% CI, 0.60-1.21]; P = .38), 51.7% vs 58.1% for death or cardiovascular hospitalization (HR, 0.83 [95% CI, 0.74-0.93]; P = .001), and 49.9% vs 69.5% for AF recurrence (HR, 0.52 [95% CI, 0.45-0.60]; P < .001).Conclusions and Relevance: Among patients with AF, the strategy of catheter ablation, compared with medical therapy, did not significantly reduce the primary composite end point of death, disabling stroke, serious bleeding, or cardiac arrest. However, the estimated treatment effect of catheter ablation was affected by lower-than-expected event rates and treatment crossovers, which should be considered in interpreting the results of the trial.Trial Registration: ClinicalTrials.gov Identifier: NCT00911508. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
24. Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial
- Author
-
Hochman, Judith S., Reynolds, Harmony R., Bangalore, Sripal, O’Brien, Sean M., Alexander, Karen P., Senior, Roxy, Boden, William E., Stone, Gregg W., Goodman, Shaun G., Lopes, Renato D., Lopez-Sendon, Jose, White, Harvey D., Maggioni, Aldo P., Shaw, Leslee J., Min, James K., Picard, Michael H., Berman, Daniel S., Chaitman, Bernard R., Mark, Daniel B., Spertus, John A., Cyr, Derek D., Bhargava, Balram, Ruzyllo, Witold, Wander, Gurpreet S., Chernyavskiy, Alexander M., Rosenberg, Yves D., and Maron, David J.
- Abstract
IMPORTANCE: It is unknown whether coronary revascularization, when added to optimal medical therapy, improves prognosis in patients with stable ischemic heart disease (SIHD) at increased risk of cardiovascular events owing to moderate or severe ischemia. OBJECTIVE: To describe baseline characteristics of participants enrolled and randomized in the International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial and to evaluate whether qualification by stress imaging or nonimaging exercise tolerance test (ETT) influenced risk profiles. DESIGN, SETTING, AND PARTICIPANTS: The ISCHEMIA trial recruited patients with SIHD with moderate or severe ischemia on stress testing. Blinded coronary computed tomography angiography was performed in most participants and reviewed by a core laboratory to exclude left main stenosis of at least 50% or no obstructive coronary artery disease (CAD) (<50% for imaging stress test and <70% for ETT). The study included 341 enrolling sites (320 randomizing) in 38 countries and patients with SIHD and moderate or severe ischemia on stress testing. Data presented were extracted on December 17, 2018. MAIN OUTCOMES AND MEASURES: Enrolled, excluded, and randomized participants’ baseline characteristics. No clinical outcomes are reported. RESULTS: A total of 8518 patients were enrolled, and 5179 were randomized. Common reasons for exclusion were core laboratory determination of insufficient ischemia, unprotected left main stenosis of at least 50%, or no stenosis that met study obstructive CAD criteria on study coronary computed tomography angiography. Randomized participants had a median age of 64 years, with 1168 women (22.6%), 1726 nonwhite participants (33.7%), 748 Hispanic participants (15.5%), 2122 with diabetes (41.0%), and 4643 with a history of angina (89.7%). Among the 3909 participants randomized after stress imaging, core laboratory assessment of ischemia severity (in 3901 participants) was severe in 1748 (44.8%), moderate in 1600 (41.0%), mild in 317 (8.1%) and none or uninterpretable in 236 (6.0%), Among the 1270 participants who were randomized after nonimaging ETT, core laboratory determination of ischemia severity (in 1266 participants) was severe (an eligibility criterion) in 1051 (83.0%), moderate in 101 (8.0%), mild in 34 (2.7%) and none or uninterpretable in 80 (6.3%). Among the 3912 of 5179 randomized participants who underwent coronary computed tomography angiography, 79.0% had multivessel CAD (n = 2679 of 3390) and 86.8% had left anterior descending (LAD) stenosis (n = 3190 of 3677) (proximal in 46.8% [n = 1749 of 3739]). Participants undergoing ETT had greater frequency of 3-vessel CAD, LAD, and proximal LAD stenosis than participants undergoing stress imaging. CONCLUSIONS AND RELEVANCE: The ISCHEMIA trial randomized an SIHD population with moderate or severe ischemia on stress testing, of whom most had multivessel CAD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01471522
- Published
- 2019
- Full Text
- View/download PDF
25. Guided Antithrombotic Therapy: Current Status and Future Research Direction
- Author
-
Fuster, Valentin, primary, Bhatt, Deepak L., additional, Califf, Robert M., additional, Michelson, Alan D., additional, Sabatine, Marc S., additional, Angiolillo, Dominick J., additional, Bates, Eric R., additional, Cohen, David J., additional, Coller, Barry S., additional, Furie, Bruce, additional, Hulot, Jean-Sebastien, additional, Mann, Kenneth G., additional, Mega, Jessica L., additional, Musunuru, Kiran, additional, O'Donnell, Christopher J., additional, Price, Matthew J., additional, Schneider, David J., additional, Simon, Daniel I., additional, Weitz, Jeffrey I., additional, Williams, Marlene S., additional, Hoots, W. Keith, additional, Rosenberg, Yves D., additional, and Hasan, Ahmed A.K., additional
- Published
- 2012
- Full Text
- View/download PDF
26. Hormone replacement therapy is associated with improved survival in women with advanced heart failure
- Author
-
Lindenfeld, JoAnn, primary, Ghali, Jalal K, additional, Krause-Steinrauf, Heidi J, additional, Khan, Steven, additional, Adams, Kirkwood, additional, Goldman, Steven, additional, Peberdy, Mary Ann, additional, Yancy, Clyde, additional, Thaneemit-Chen, Surai, additional, Larsen, Rhonda L, additional, Young, James, additional, Lowes, Brian, additional, and Rosenberg, Yves D, additional
- Published
- 2003
- Full Text
- View/download PDF
27. Influence of etiology on the survival advantage of women with advanced heart failure
- Author
-
Ghali, Jalal K., primary, Krause-Steinrauf, Heidi J., additional, Adams, Kirkwood F., additional, Khan, Steven S., additional, Rosenberg, Yves D., additional, Yancy, Clyde W., additional, Young, James B., additional, Goldman, Steven, additional, Peberdy, Mary A., additional, and Lindenfeld, JoAnn, additional
- Published
- 2003
- Full Text
- View/download PDF
28. The impact of gender on prognosis in patients with advanced heart failure
- Author
-
Ghali, Jalal K., primary, Krause-Steinrauf, Heidi, additional, Adams, Kirkwood F., additional, Goldman, Steven, additional, Khan, Steven S., additional, Peberdy, Mary A., additional, Rosenberg, Yves D., additional, Yancy, Clyde W., additional, Young, James B., additional, and Lindenfeld, JoAnn, additional
- Published
- 2002
- Full Text
- View/download PDF
29. Therapy of Atrial Fibrillation: Rhythm Control Versus Rate Control
- Author
-
CARLSSON, JOERG, primary, NEUZNER, JOERG, additional, and ROSENBERG, YVES D., additional
- Published
- 2000
- Full Text
- View/download PDF
30. Ejection Fraction and Risk of Thromboembolic Events in Patients With Systolic Dysfunction and Sinus Rhythm: Evidence for Gender Differences in the Studies of Left Ventricular Dysfunction Trials
- Author
-
Dries, Daniel L., primary, Rosenberg, Yves D., additional, Waclawiw, Myron A., additional, and Domanski, Michael J., additional
- Published
- 1997
- Full Text
- View/download PDF
31. Guided Antithrombotic Therapy
- Author
-
Fuster, Valentin, Bhatt, Deepak L., Califf, Robert M., Michelson, Alan D., Sabatine, Marc S., Angiolillo, Dominick J., Bates, Eric R., Cohen, David J., Coller, Barry S., Furie, Bruce, Hulot, Jean-Sebastien, Mann, Kenneth G., Mega, Jessica L., Musunuru, Kiran, O'Donnell, Christopher J., Price, Matthew J., Schneider, David J., Simon, Daniel I., Weitz, Jeffrey I., Williams, Marlene S., Hoots, W. Keith, Rosenberg, Yves D., and Hasan, Ahmed A.K.
- Published
- 2012
- Full Text
- View/download PDF
32. Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
- Author
-
PEACE (Prevention of Events with Angiotensin Converting Enzyme Inhibition) Trial Investigators, Braunwald, Eugene, Domanski, Michael J, Fowler, Sarah E, Geller, Nancy L, Gersh, Bernard J, Hsia, Judith, Pfeffer, Marc A, Rice, Madeline M, Rosenberg, Yves D, Rouleau, Jean L, and PEACE Trial Investigators
- Abstract
Background: Angiotensin-converting-enzyme (ACE) inhibitors are effective in reducing the risk of heart failure, myocardial infarction, and death from cardiovascular causes in patients with left ventricular systolic dysfunction or heart failure. ACE inhibitors have also been shown to reduce atherosclerotic complications in patients who have vascular disease without heart failure.Methods: In the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial, we tested the hypothesis that patients with stable coronary artery disease and normal or slightly reduced left ventricular function derive therapeutic benefit from the addition of ACE inhibitors to modern conventional therapy. The trial was a double-blind, placebo-controlled study in which 8290 patients were randomly assigned to receive either trandolapril at a target dose of 4 mg per day (4158 patients) or matching placebo (4132 patients).Results: The mean (+/-SD) age of the patients was 64+/-8 years, the mean blood pressure 133+/-17/78+/-10 mm Hg, and the mean left ventricular ejection fraction 58+/-9 percent. The patients received intensive treatment, with 72 percent having previously undergone coronary revascularization and 70 percent receiving lipid-lowering drugs. The incidence of the primary end point--death from cardiovascular causes, myocardial infarction, or coronary revascularization--was 21.9 percent in the trandolapril group, as compared with 22.5 percent in the placebo group (hazard ratio in the trandolapril group, 0.96; 95 percent confidence interval, 0.88 to 1.06; P=0.43) over a median follow-up period of 4.8 years.Conclusions: In patients with stable coronary heart disease and preserved left ventricular function who are receiving "current standard" therapy and in whom the rate of cardiovascular events is lower than in previous trials of ACE inhibitors in patients with vascular disease, there is no evidence that the addition of an ACE inhibitor provides further benefit in terms of death from cardiovascular causes, myocardial infarction, or coronary revascularization. [ABSTRACT FROM AUTHOR]- Published
- 2004
33. Long-term effects of intensive glucose lowering on cardiovascular outcomes.
- Author
-
Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, and Friedewald WT
- Subjects
- Adult, Aged, Cardiovascular Diseases etiology, Cardiovascular Diseases mortality, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 complications, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Myocardial Infarction epidemiology, Myocardial Infarction etiology, Proportional Hazards Models, Stroke epidemiology, Stroke etiology, Treatment Outcome, Cardiovascular Diseases prevention & control, Diabetes Mellitus, Type 2 drug therapy, Glycated Hemoglobin analysis, Hypoglycemic Agents administration & dosage
- Abstract
Background: Intensive glucose lowering has previously been shown to increase mortality among persons with advanced type 2 diabetes and a high risk of cardiovascular disease. This report describes the 5-year outcomes of a mean of 3.7 years of intensive glucose lowering on mortality and key cardiovascular events., Methods: We randomly assigned participants with type 2 diabetes and cardiovascular disease or additional cardiovascular risk factors to receive intensive therapy (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a level of 7 to 7.9%). After termination of the intensive therapy, due to higher mortality in the intensive-therapy group, the target glycated hemoglobin level was 7 to 7.9% for all participants, who were followed until the planned end of the trial., Results: Before the intensive therapy was terminated, the intensive-therapy group did not differ significantly from the standard-therapy group in the rate of the primary outcome (a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) (P=0.13) but had more deaths from any cause (primarily cardiovascular) (hazard ratio, 1.21; 95% confidence interval [CI], 1.02 to 1.44) and fewer nonfatal myocardial infarctions (hazard ratio, 0.79; 95% CI, 0.66 to 0.95). These trends persisted during the entire follow-up period (hazard ratio for death, 1.19; 95% CI, 1.03 to 1.38; and hazard ratio for nonfatal myocardial infarction, 0.82; 95% CI, 0.70 to 0.96). After the intensive intervention was terminated, the median glycated hemoglobin level in the intensive-therapy group rose from 6.4% to 7.2%, and the use of glucose-lowering medications and rates of severe hypoglycemia and other adverse events were similar in the two groups., Conclusions: As compared with standard therapy, the use of intensive therapy for 3.7 years to target a glycated hemoglobin level below 6% reduced 5-year nonfatal myocardial infarctions but increased 5-year mortality. Such a strategy cannot be recommended for high-risk patients with advanced type 2 diabetes. (Funded by the National Heart, Lung and Blood Institute; ClinicalTrials.gov number, NCT00000620.).
- Published
- 2011
- Full Text
- View/download PDF
34. Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
- Author
-
Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, and Rouleau JL
- Subjects
- Aged, Angiotensin-Converting Enzyme Inhibitors adverse effects, Angiotensin-Converting Enzyme Inhibitors pharmacology, Blood Pressure drug effects, Cardiovascular Diseases mortality, Cardiovascular Diseases prevention & control, Coronary Disease mortality, Coronary Disease physiopathology, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Indoles adverse effects, Indoles pharmacology, Male, Middle Aged, Myocardial Infarction prevention & control, Myocardial Revascularization, Renin-Angiotensin System drug effects, Ventricular Function, Left, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Coronary Disease drug therapy, Indoles therapeutic use
- Abstract
Background: Angiotensin-converting-enzyme (ACE) inhibitors are effective in reducing the risk of heart failure, myocardial infarction, and death from cardiovascular causes in patients with left ventricular systolic dysfunction or heart failure. ACE inhibitors have also been shown to reduce atherosclerotic complications in patients who have vascular disease without heart failure., Methods: In the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial, we tested the hypothesis that patients with stable coronary artery disease and normal or slightly reduced left ventricular function derive therapeutic benefit from the addition of ACE inhibitors to modern conventional therapy. The trial was a double-blind, placebo-controlled study in which 8290 patients were randomly assigned to receive either trandolapril at a target dose of 4 mg per day (4158 patients) or matching placebo (4132 patients)., Results: The mean (+/-SD) age of the patients was 64+/-8 years, the mean blood pressure 133+/-17/78+/-10 mm Hg, and the mean left ventricular ejection fraction 58+/-9 percent. The patients received intensive treatment, with 72 percent having previously undergone coronary revascularization and 70 percent receiving lipid-lowering drugs. The incidence of the primary end point--death from cardiovascular causes, myocardial infarction, or coronary revascularization--was 21.9 percent in the trandolapril group, as compared with 22.5 percent in the placebo group (hazard ratio in the trandolapril group, 0.96; 95 percent confidence interval, 0.88 to 1.06; P=0.43) over a median follow-up period of 4.8 years., Conclusions: In patients with stable coronary heart disease and preserved left ventricular function who are receiving "current standard" therapy and in whom the rate of cardiovascular events is lower than in previous trials of ACE inhibitors in patients with vascular disease, there is no evidence that the addition of an ACE inhibitor provides further benefit in terms of death from cardiovascular causes, myocardial infarction, or coronary revascularization., (Copyright 2004 Massachusetts Medical Society.)
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.